China approves Eli Lilly’s weight-loss pill orforglipron
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓China approved Eli Lilly’s weight-loss pill orforglipron on Thursday, the country's medicine regulator said.
- ✓This move gives the drugmaker a lead over rival Novo Nordisk in the world's second-largest pharmaceutical market.
- ✓Many patients prefer pills over injections, and Lilly got ahead by being the first to apply for approval.
Story at a Glance
- Category
- Indian Markets
- Reported By
- Reuters
- Reading Speed
- 1 Minute(s)
- Market Focus
- India Economy
SHANGHAI, Nov 12 (Reuters) - China has approved Eli Lilly's weight-loss pill orforglipron, the country's medicine regulator said on Thursday, giving the drugmaker a leg up on Danish rival Novo Nordisk (NOVOb.CO), opens new tab in the world's second-largest pharmaceutical market.
Lilly's pill will compete for market share in China with the once-weekly GLP-1 weight-loss injections from Novo, Pfizer (PFE.N), opens new tab, and local firm Innovent Biologics (1801.HK), opens new tab, as the country's National Health Commission has said the rate of overweight or obese people could reach more than 65% by 2030.
Sign up here.
Novo and Lilly believe weight-loss pills could attract patients reluctant to use injections, although Novo's own oral Wegovy has not yet been approved in China. Lilly was first to apply with orforglipron.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Reuters
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.